NGM Bio to Present at Two Upcoming Investor Conferences
NGM Biopharmaceuticals (NGM) announced that CEO David J. Woodhouse, Ph.D., will present at two investor conferences. The events are the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 4:40 PM ET, and the Raymond James Human Health Innovation Conference 2021 on June 21, 2021, at 2:00 PM ET. A live webcast will be available on NGM's website, with archived replays for 90 days. NGM focuses on developing novel therapeutics targeting liver, metabolic, retinal diseases, and cancer, with six disclosed programs, including four in advanced studies.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at two upcoming investor conferences.
Wednesday, June 9, 2021
Event: Goldman Sachs 42nd Annual Global Healthcare Conference
Time: 4:40 pm ET
Monday, June 21, 2021
Event: Raymond James Human Health Innovation Conference 2021
Time: 2:00 pm ET
A live webcast of these presentations will be available under the Investors and Media section of NGM’s website at https://ir.ngmbio.com/events-presentations. A replay of the presentation will be archived on NGM’s site for 90 days following the event.
About NGM Biopharmaceuticals, Inc.
NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry. All of our therapeutics have been generated by our in-house discovery engine; today, we have six disclosed programs, including four in Phase 2 or 2b studies, across three therapeutics areas. Visit us at www.ngmbio.com for more information.
| Investor Contact: Alex Schwartz ir@ngmbio.com | Media Contact: Liz Melone media@ngmbio.com |
FAQ
What events will NGM Biopharmaceuticals present at in June 2021?
What is the time for NGM's presentation at the Goldman Sachs conference?
What is the focus of NGM Biopharmaceuticals?
How many programs does NGM have in advanced studies?
Where can I watch NGM's conference presentations?
